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Purpose: Access to claims databases provides an opportunity to study medication
use and safety during pregnancy. We developed an algorithm to identify pregnancy
episodes in the French health care databases and applied it to study antiepileptic drug
(AED) use during pregnancy between 2007 and 2014.
Methods: The algorithm searched the French health care databases for discharge
diagnoses andmedical procedures indicative of completion of a pregnancy. To differen-
tiate claims associated with separate pregnancies, an interval of at least 28 weeks was
required between 2 consecutive pregnancies resulting in a birth and 6 weeks for termi-
nations of pregnancy. Pregnancy outcomes were categorized into live births, stillbirths,
elective abortions, therapeutic abortions, spontaneous abortions, and ectopic pregnan-
cies. Outcome dates and gestational ages were used to calculate pregnancy start dates.
Results: According to our algorithm, live birth was the most common pregnancy
outcome (73.9%), followed by elective abortion (17.2%), spontaneous abortion
(4.2%), ectopic pregnancy (1.1%), therapeutic abortion (1.0%), and stillbirth (0.4%).
These results were globally consistent with French official data. Among 7 559 701
pregnancies starting between 2007 and 2014, corresponding to 4 900 139 women,
6.7 per 1000 pregnancies were exposed to an AED. The number of pregnancies
exposed to older AEDs, comprising the most teratogenic AEDs, decreased throughout
the study period (−69.4%), while the use of newer AEDs increased (+73.4%).
Conclusions: We have developed an algorithm that allows identification of a large
number of pregnancies and all types of pregnancy outcomes. Pregnancy outcome and
start dateswere accurately identified, andmaternal data could be linked to neonatal data.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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pregnancyKEY POINTS
• Access to claims databases provides an opportunity to
study medication use and safety during pregnancy.
• Few articles have been specifically devoted to
identification of pregnancies in claims databases, and
no algorithms based on the French health care
databases have been published.
• We have developed an algorithm that captured all types
of pregnancy outcome and accurately identified
pregnancy episodes.
• Among 7 559 701 pregnancies starting between 2007
and 2014, 6.7 per 1000 pregnancies were exposed to
an AED.1 | INTRODUCTION
The exclusion of pregnant women from clinical trials results in a lack of
information about the effects of medication use during pregnancy on
maternal and fetal health. Access to claims databases therefore pro-
vides an opportunity to study medication use and safety during preg-
nancy. These databases are particularly useful, as these studies, often
concerning rare exposures and rare birth outcomes, require large data
sources. Routine post‐marketing research is also possible, since infor-
mation on a wide range of outcomes and all prescription drugs pre-
scribed or dispensed during pregnancy is available. Ascertainment of
medication use is based on pharmacy claims data and is independent
of maternal or infant outcomes, which avoids parental recall bias.1
However, claims databases are usually not built for research pur-
poses and algorithmic approaches must be developed in order to iden-
tify pregnancy episodes and related outcomes.2 A few articles have
been specifically devoted to this challenge, using the Clinical Practice
Research Datalink2,3 or North American claims databases.1,4-8 In
France, despite growing interest in pregnancy research using claims
databases,9-16 no algorithm has yet been published. However, some
studies have explicitly reported the discharge diagnoses or medical
procedures used to identify pregnancies.9-11,13,16 Most studies were
restricted to births, and only a few studies included abortion and
ectopic pregnancies.9,12,14,16
The primary objective of this study was therefore to develop an
algorithm to identify pregnancy episodes and related outcomes using
the French health care databases, which covers 99% of the 67 million
inhabitants in France.17 The secondary objective was to apply this algo-
rithm to the analysis of antiepileptic drug (AED) use during pregnancy in
France between 2007 and 2014. Studying AED use during pregnancy is
of particular interest, as prenatal exposure to some older AEDs has been
found to be associated with increased risks of major congenital
malformations,18 and prenatal exposure to valproic acid has been found
to be associated with an increased risk of autism spectrum disorder.192 | METHODS
2.1 | Data source
This study was conducted using the French national health insurance
information system (SNIIRAM), which consists of 2 French nationwide
datasets linked by a unique patient identifier: the French national
health insurance database (DCIR) and the French hospital discharge
database (PMSI). French national health insurance covers the entire
French population and is divided into several specific schemes, includ-
ing the general scheme for salaried workers (87% of the population),
the self‐employed workers scheme (6%), the farmers scheme (5%),
and other additional schemes covering the remaining 2%.20The DCIR database contains all individualized and anonymous
health care claims reimbursed by French National Health Insurance.
These claims include, in particular, dispensed drugs and medical proce-
dures. The DCIR database also collects patient data such as age, gen-
der, and eligibility for 100% health insurance coverage for serious and
costly long‐term diseases (LTD) coded according to the International
Classification of Diseases, 10th Revision (ICD‐10), but does not con-
tain other outpatient medical indications. The PMSI database provides
detailed medical information on all admissions in public and private
hospitals in France, including discharge diagnosis ICD‐10 codes and
medical procedures coded according to the French medical classifica-
tion for clinical procedures (CCAM).2.2 | Algorithm
Pregnancies were identified on the basis of their outcome from the
DCIR database for outpatient medical abortions and from the PMSI
database for all other pregnancy outcomes. The algorithm searched
the databases for discharge diagnoses and medical procedures indica-
tive of completion of a pregnancy coded between 2007 and 2015.
Diagnoses and procedures are presented inTable 1. All records associ-
ated with unknown women identifiers, which could not be linked to
any other data, were discarded. A flowchart describing the algorithm
is available in Supporting Information (supplementary figure 1).
In the first step, all records of codes indicative of completion of a
pregnancy in the PMSI database were grouped into 2 categories: (1)
births (end of pregnancy ≥22 weeks after the last menstrual period
[LMP]); (2) any terminations of pregnancy <22 weeks after the LMP.
Codes representing the same pregnancy were then removed: for each
woman, duplicate records were addressed separately in the 2 groups
by choosing the last code as the pregnancy outcome within a
predetermined time‐frame. A 28‐week span was used for births, and
TABLE 1 Data used to identify pregnancy outcomes in the SNIIRAM databases
Live births Associated diagnoses Z37, Z3900a or principal diagnoses O80, O81, O82, O83, O84
OR delivery procedureb
WITHOUT diagnoses indicative of stillbirth or therapeutic abortions ≥22 weeks after the LMP
Stillbirths Associated diagnoses Z37.1, Z37.3, Z37.4, Z37.6, Z37.7 WITHOUT principal diagnosis O35 before March 2011
Associated diagnoses Z37.10, Z37.30, Z37.40, Z37.60, Z37.70c after March 2011
Elective abortions
Inpatient elective abortions Principal diagnoses O04, O05, O06, O07
AND procedure indicative of inpatient abortiond
AND associated diagnosis Z640
Outpatient medical abortions Procedure indicative of outpatient medical abortione
Therapeutic abortions
<22 weeks after the LMP Principal diagnoses O04, O05, O06, O07
AND procedure indicative of inpatient abortiond
WITHOUT associated diagnosis Z640
≥22 weeks after the LMP Associated diagnoses Z37.1, Z37.3, Z37.4, Z37.6, Z37.7 AND principal diagnosis O35 before March 2011
Associated diagnoses Z37.11, Z37.31, Z37.41, Z37.61, Z37.71c after march 2011
Other abortions Principal diagnoses O04, O05, O06, O07
WITHOUT procedure indicative of inpatient abortiond
Spontaneous abortions Principal diagnosis O03
Ectopic pregnancies Principal diagnosis O00
OR procedure indicative of ectopic pregnancyf
Othersg Principal diagnosis O01, O02
Note:
Stillbirth = death of a fetus with a gestational age ≥ 22 weeks after the LMP or with a birth weight ≥ 500 g.
Spontaneous abortion = death of a fetus with a gestational age < 22 weeks after the LMP and a birth weight < 500 g.
Elective abortion = termination of pregnancy at the woman's request for reasons other than maternal health or fetal disease, possible until 14 weeks after
the LMP in France.
aCare and examination immediately after delivery outside hospital.
bCCAM codes JQGD010, JQGD012, JQGD004, JQGD001, JQGD003, JQGD008, JQGD013, JQGD005, JQGD002, JQGD007, JQGA002, JQGA004,
JQGA003, JQGA005.
cThe extension “0” indicates stillbirth, excluding therapeutic abortion and “1” indicates therapeutic abortion.
dCCAM codes JNJD001, JNJD002 (surgical abortion), JNJP001 (medical abortion).
eOutpatient procedure codes 2422, 3329 (management of medical abortion), 2415 (mifepristone), 2416 (prostaglandin), available only for the general
scheme before 2009.
fCCAM codes JJFA001, JJFC001 (Salpingectomy), JJJA002, JJJC002 (fimbrial evacuation), JJLJ001 (In situ injection of methotrexate), JJPA001, JJPC001
(salpingostomy), JQGA001 (Removal of abdominal pregnancy more than 13 weeks after the LMP).
gHydatidiform mole or other abnormal products of conception.
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pregnancies within these time‐frames were deemed implausible.21
In the second step, all records of codes related to outpatient med-
ical abortions were identified in the DCIR database, and duplicate
records were addressed in a similar way to duplicate records of termi-
nations of pregnancy in the PMSI database. Only outpatient medical
abortions performed outside a 6‐week span before and after a termi-
nation of pregnancy identified in the first step were included.
In the third step, terminations of pregnancy occurring during a preg-
nancy resulting in a birth were excluded. Terminations of pregnancy
occurring during the first 10 weeks after a birth were also excluded.21
Pregnancy outcomes were finally categorized into live births, still-
births, elective abortions (both inpatient and outpatient), therapeutic
abortions, spontaneous abortions, ectopic pregnancies, and other out-
comes (hydatidiform mole or other abnormal products of conception).
2.2.1 | Pregnancy start date
Pregnancy start dates were calculated from the following:1. pregnancy outcome dates. Exact admission, discharge, and medi-
cal procedure dates have been recorded in the PMSI database
since 2009 (supplementary figure 2). When a medical procedure
was performed, the exact procedure date was used as the out-
come date, which was the case for 97.0% of all births and
91.7% of all inpatient induced abortions. Otherwise, the exact
admission date was used. Before 2009, only discharge months
were available in the PMSI database, and the outcome date was
considered to be the fifteenth day of the discharge month.
2. gestational ages or numbers of days after the LMP. Gestational
age has been recorded in the PMSI database since March
200822 and exhaustively since March 2010 for all births. It is
expressed in completed gestational weeks and has been vali-
dated,23 with a high positive predictive value.24 For inpatient
abortions and other pregnancy outcomes, the number of days
after the LMP has been recorded since March 201122 and
exhaustively since March 2012 (supplementary figure 2). The
median gestational ages observed in the PMSI database in 2014
766 BLOTIÈRE ET AL.were therefore used to replace missing gestational ages or num-
bers of days after the LMP according to the type of pregnancy
outcome. For this purpose, abortions were further detailed
according to trimester and method (supplementary table 1).
This pregnancy start date was compared with an estimated con-
ception date recorded in the DCIR database independently of the
information available in the PMSI database. This estimated conception
date is reported only for women entitled to maternity leave, which
excludes all pregnancies ending before 22 weeks and self‐employed
workers, regardless of the pregnancy outcome.2.2.2 | Comparison with official national data
The number of pregnancies identified by the algorithm was compared
with official national data for 2014. Official data on live births are pub-
lished by the National Institute of Statistics and Economic Studies
(INSEE), which records all births occurring in France. Data on
therapeutic abortions are published by the French Biomedicine
Agency and correspond to the number of authorized abortions and
not the total number of abortions actually performed. Official data
on elective abortions, corresponding to the number of abortion proce-
dures and not the number of distinct pregnancies, are based on the
French health care databases, not allowing any valid comparisons.TABLE 2 Distribution of pregnancy episodes by maternal age, type
of outcome and twin pregnancies over the 2007 to 2015 study period
n %
Maternal age at the end of pregnancy (years)
Mean (±STD) 29.5 (± 5.9)
12–19 425 596 4.4%
20–29 4 460 709 46.2%2.2.3 | Linkage between maternal and neonatal data
Linkage between maternal and neonatal data has been possible in the
PMSI database since 2011 by means of a common identifier shared by
the mother and her child and present in both the delivery stay and the
birth stay. As a birth stay is coded in the PMSI database only for
children with a gestational age ≥ 22 weeks after the LMP, this linkage
is possible for live births, stillbirths, and therapeutic abortions after
22 weeks.
30–39 4 283 905 44.4%
40–49 471 374 4.9%
50–59 2307 0.0%
Unknown 3952 0.0%
Pregnancy outcome
Live births 7 126 842 73.9%
Stillbirths 42 460 0.4%
Elective abortions 1 656 987 17.2%
Inpatient elective abortions 1 390 962 14.4%
Outpatient medical abortions 266 025 2.8%
Therapeutic abortions 93 449 1.0%
<22 weeks after the LMP 69 364 0.7%
≥22 weeks after the LMP 24 085 0.2%
Total abortionsa 1 830 965 19.0%
Spontaneous abortions 407 925 4.2%
Ectopic pregnancies 108 529 1.1%
Othersb 131 122 1.4%
Total pregnancy episodes 9 647 843
Total pregnant women 6 230 200
Twin pregnancies (live births) 119 404 1.7%
aIncluding “other abortion” type.
bHydatidiform mole or other abnormal products of conception.2.3 | Antiepileptic drug use
As women may have multiple pregnancies during the study period, the
unit of analysis was a pregnancy. All pregnancies starting between
2007 and 2014, regardless of the outcome, were eligible for inclusion.
The mother had to have continuous health insurance enrolment for a
1‐year period before pregnancy. The study was based on the national
health insurance general scheme to ensure complete availability of
data throughout the study period.
AEDs were defined according to the World Health Organization
Anatomical Therapeutic Chemical classification (supplementary table
2). AEDs marketed before the early 1990s are traditionally referred
to as “older” AED, whilst drugs that were introduced later are referred
to as “newer” AED.25 Women were considered to be exposed during
the 30 days following dispensing.
Prevalence of AED use during pregnancy was assessed between
2007 and 2014. Prevalence was defined as the number of pregnancies
exposed to AEDs per 1000 pregnancies. Prevalence rates were calcu-
lated overall, by drug group (older versus newer AEDs) and by Ana-
tomical Therapeutic Chemical classes. Drug use was also described
by trimester of pregnancy: day 0 to day 90 (first trimester), day 91to day 181 (second trimester), and day 182 until delivery (third trimes-
ter). If a period of exposure began in a given trimester and carried over
into the subsequent trimester, both trimesters were considered to be
exposed. Trends were also investigated, especially for pregnant
women with epilepsy, identified with LTD codes G40 and G41. All
epileptic women without epilepsy recorded as an LTD were missed.
A sensitivity analysis was conducted to account for uncertainty in
estimating the time period during which a woman was pregnant: a
lower limit for prevalence rates was calculated using the 5th percentile
of gestational age instead of the median when gestational age was
missing and an upper limit was calculated using the 95th percentile
of gestational age.3 | RESULTS
3.1 | Algorithm
The algorithm identified 6 230 200 women who had 9 647 843 preg-
nancies between 2007 and 2015 (Table 2). Mean age at the end of
pregnancy was 29.5 years. Live birth was the most common preg-
nancy outcome (73.9%), followed by elective abortion (17.2%), sponta-
neous abortion (4.2%), ectopic pregnancy (1.1%), therapeutic abortion
(1.0%), and stillbirth (0.4%). From 2009 onwards, the estimated con-
ception date available for women entitled to maternity leave was
FIGURE 1 Proportion of pregnancies exposed to the most
commonly used AEDs according to trimester of pregnancy
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78.7% of pregnancies and did not differ by more than 1 gestational
week for 97.3% of pregnancies.
When taking into account multiple births and pregnancies associ-
ated with unknown mother identifiers, the algorithm missed only
0.05% of all live births declared in 2014 (supplementary table 3). The
number of pregnancies ending in therapeutic abortions was higher
than the official number of authorized abortions. The proportion of
unknown mother identifiers was the highest for elective abortions
(8% in 2014).
Linkage between maternal and neonatal data was available only
for public hospitals in 2011 and has been available for both public
and private hospitals since 2012. Linkage rates increased between
2012 and 2015 from 88.5% to 95.2% (Table 3). Linkage rates were 5
points higher for live births than for stillbirths or therapeutic abortions
after 22 weeks during the period 2011 to 2015.FIGURE 2 Proportion of pregnancies exposed to all types of AEDs
and to older and newer AEDs.
Dotted lines represent the proportion of pregnancies exposed to AED
using the 5th and 95th percentile of gestational age instead of the
median (sensitivity analysis)3.2 | Antiepileptic drug use
Over the study period, 7 559 701 pregnancies, representing
4 900 139 pregnant women, met the inclusion and exclusion criteria.
In this population, 6.7 per 1000 pregnancies were exposed to AEDs:
3.2 to older AEDs and 4.0 to newer AEDs (supplementary table 4).
The most commonly used older AEDs were clonazepam, valproic acid,
carbamazepine, and phenobarbital with prevalence rates of 1.5, 1.1,
0.6, and 0.1, respectively. The most commonly used newer AEDs were
lamotrigine, pregabalin, levetiracetam, topiramate, gabapentin, and
oxcarbazepine with prevalence rates of 1.9, 1.0, 0.6, 0.4, 0.3, and
0.2, respectively. Prevalence rates were < 0.1 for the remaining AEDs.
Among pregnancies ending in a live birth, 6.3 per 1000 pregnancies
were exposed to AEDs.
Exposure to valproic acid, carbamazepine, clonazepam, and
pregabalin decreased after the first trimester of pregnancy, while
exposure to lamotrigine and levetiracetam remained stable throughout
pregnancy (Figure 1).
The number of pregnancies exposed to older AEDs decreased
over the study period (−69.4%) (Figure 2), mainly driven by the declin-
ing use of clonazepam, valproic acid, and phenobarbital (Figure 3). The
use of newer AEDs increased (+73.4%) concomitantly with this
decreased use of older AEDs, and newer AEDs became more
commonly used than older AEDs after 2010. In particular, the use of
levetiracetam, pregabalin, and lamotrigine rapidly increased over the
study period. The proportion of women with epilepsy as an LTDTABLE 3 Linkage rates between maternal and neonatal data for all
births (live births, stillbirths, and therapeutic abortions ≥22 weeks
after the LMP) by calendar year
Live
Birth Stillbirth
Therapeutic Abortion ≥
22 Weeks after the LMP
Total
Births
2011 57.9% 55.7% 60.6% 57.9%
2012 88.5% 81.3% 78.9% 88.5%
2013 91.8% 86.4% 85.0% 91.8%
2014 93.9% 88.5% 88.6% 93.8%
2015 95.2% 89.7% 91.0% 95.2%
Total 2011–2015 85.3% 79.9% 80.5% 85.3%among newer AED users decreased from 29.7% to 23.3% between
2007 and 2014 (Figure 4).
Using the 5th or 95th percentile of gestational age instead of the
median did not dramatically change the results (Figure 2).4 | DISCUSSION
4.1 | Algorithm
This is the first algorithm to be developed in order to identify pregnan-
cies from the French health care databases. As the French health care
databases cover almost all of the French population, this algorithm is a
useful tool to conduct studies concerning rare drug exposures or
maternal conditions and rare maternal or neonatal outcomes. The
algorithm captured all types of pregnancy outcome (live birth, stillbirth,
elective abortion, therapeutic abortion, spontaneous abortion, and
ectopic pregnancy), allowing not only live births but also other
pregnancy outcomes to be included in such studies.
FIGURE 3 Proportion of pregnancies exposed to the most
commonly used older (A) and newer (B) AEDs
FIGURE 4 Proportion of women with epilepsy LTD status among
newer and older AED users after excluding clonazepam from the
analysis.
Clonazepam was excluded from the analysis because off‐label use was
common until the French health authorities took measures to limit off‐
label use in November 2011
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pared with official data for live births and therapeutic abortions, dem-
onstrating a high degree of agreement for live births, with a difference
of only 2000 pregnancies in 2014. This difference can probably be
explained by home deliveries, although codes related to examinationafter delivery outside hospital were included in the algorithm. Such a
comparison was not possible for elective abortions.
The algorithm accurately identified the time period during which
a woman was pregnant, as shown by the high concordance rate
between the estimated conception date and the pregnancy start date
calculated by the algorithm, as a result of the availability of exact
pregnancy outcome dates since 2009 and gestational age since
March 2010 for births and March 2012 for other outcomes. Unlike
many other claims databases, gestational age is directly available in
the PMSI database, without the need for linkage to other administra-
tive data, such as vital records.26 Accurate identification of pregnancy
episodes from March 2010 for births and March 2012 for other
outcomes should limit misclassification of medication exposure
during pregnancy, especially during critical trimesters or months of
pregnancy.
Linkage between maternal and neonatal data has been available in
the PMSI since 2011 for births ≥22 weeks after the LMP, including
stillbirths and therapeutic abortions. The linkage rate was greater than
95% in 2015. Deterministic linkage was possible without the need for
probabilistic linkage. This linkage is essential to study the effects of
medication exposure or a given condition during pregnancy on neona-
tal outcomes. The only nationwide study using this linkage published
to date was designed to assess the association between maternal
gestational diabetes and the risk of adverse neonatal outcomes, such
as perinatal death, asphyxia, macrosomia, etc.15
This study presents 2 main limitations. First of all, although health
care claims data can be exhaustive, readily available, and reasonably
inexpensive, making them attractive for large‐scale studies, they are
not designed for research purposes, unlike registries or, more gener-
ally, ad hoc prospectively collected databases, and can be susceptible
to misclassification.20,27 In our study, the proposed algorithm was
based on ICD‐10 diagnosis codes and medical procedure codes that
may be subject to coding errors, and data from medical records could
not be used to validate pregnancy outcomes. For instance, the excess
number of therapeutic abortions identified by the algorithm could be
explained by the omission of the diagnosis code “Problems related to
unwanted pregnancy”. However, as the PMSI database is used for
planning and funding purposes and is subject to coding quality control,
coding errors should therefore be limited.
In addition, some pregnancies may not have been identified, par-
ticularly anonymized abortions, which can be requested by minors28
and which represented up to 8% of all elective abortions in 2014.
Spontaneous abortions which are not managed in hospital were also
missed: the proportion of spontaneous abortions identified with the
algorithm was 4.2%, while spontaneous abortion occurs in approxi-
mately 15% of all clinically recognized pregnancies.29 Finally,
stillbirths might have been slightly overestimated before March
2011 because therapeutic abortions ≥22 weeks after the LMP for
maternal indications, which are far less common than therapeutic
abortions for fetal indications, cannot be distinguished from
stillbirths.
A second limitation of this study is that exact pregnancy outcome
dates were not available before 2009, which could result in imprecise
pregnancy start dates. However, the overall prevalence of AED use in
our study did not differ by more than 1.3% when the first day or last
BLOTIÈRE ET AL. 769day of the month of discharge was used instead of the 15th day.
Another source of uncertainty is the absence of recording of gesta-
tional age before 2010 for births and 2013 for other outcomes, requir-
ing for instance the use of median gestational ages observed after
2013 in the PMSI database: exposure misclassification could not be
ruled out, especially for drugs that are not used chronically like
AEDs.30 In particular, preterm deliveries could not be identified when
gestational age was missing. Assigning the same median gestational
age to all preterm or full‐term live births therefore resulted in too long
durations of pregnancy for preterm deliveries. However, the 5th
percentile of gestational age was used in a sensitivity analysis and
did not substantially change the results.4.2 | Antiepileptic drug use
This algorithm was implemented in a population of almost 5 million
women starting a pregnancy between 2007 and 2014. Over the study
period, 6.7 per 1000 pregnancies were exposed to an AED, compared
with 8.3 in a previous study based on a small sample of the SNIIRAM
database.16 The prevalence rate, restricted to live births, was 6.3 per
1000 pregnancies, which was higher than those observed in 7
European regions, with prevalence rates ranging from 4.3 in The
Netherlands to 6.0 in Wales.31 However, these prevalence rates
cannot be compared directly, as the indications for AEDs vary from
1 country to another. An American study based on administrative
health plan data found that 2% of women who gave birth between
2001 and 2007 were exposed to an AED during pregnancy, but mainly
for the treatment of psychiatric or pain disorders.32
The decreased use of older AEDs and the increased use of
newer AEDs between 2007 and 2014 were in line with worldwide
trends.32-34 In particular, the proportion of pregnancies exposed to
valproic acid, the most teratogenic AED,18 decreased between
2007 and 2014.19,33-36 These trends could be explained by changes
in practice guidelines and improved medical knowledge, but other
explanations such as changes in population cannot be ruled out.
However, valproic acid use during pregnancy remained high in
France, particularly during the first trimester of pregnancy, corre-
sponding to the period of greatest risk for the teratogenic effects
of medications. As the indication for which a drug is prescribed is
not available in the DCIR database, we assessed AED use among
women with epilepsy LTD status and observed a decrease in the pro-
portion of women with epilepsy among newer AEDs users between
2007 and 2014, suggesting that the increased use of newer AEDs
could be partially explained by a growing use of these drugs in indi-
cations other than epileptic disorders, as already documented in Italy
and Denmark.37,385 | CONCLUSION
We have developed an algorithm based on claims data with a number
of key strengths for the study of medication use and safety in preg-
nancy research, especially for pregnancies ending more than 22 weeks
after the LMP: the availability of a large study population, accurate
calculation of pregnancy outcome and start dates since March 2010,and availability of linkage between maternal and neonatal data since
January 2011.
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